Dextromethorphan Adverse Effects in Autism Spectrum Disorder
Dextromethorphan is generally well-tolerated in individuals with autism spectrum disorder, with the most common adverse effects being dose-related neurological, cardiovascular, and gastrointestinal disturbances, though serious adverse events are rare.
Safety Profile in ASD Population
The available evidence specifically examining dextromethorphan in ASD populations demonstrates a reassuring safety profile:
In a 2020 randomized, placebo-controlled crossover trial of dextromethorphan/quinidine (DM/Q) in 14 autistic adults, there were no serious adverse events reported 1. This represents the highest quality evidence specific to ASD populations.
An earlier 2007 pilot study in 8 children with autism using a double-blind, placebo-controlled design similarly found dextromethorphan to be safe, though efficacy was limited to a subset of participants with ADHD-like behavioral profiles 2.
General Adverse Effect Profile
Based on over 30 years of clinical experience with dextromethorphan, the general adverse event profile includes 3:
Most Common Adverse Effects (dose-related):
- Neurological disturbances: Dizziness, drowsiness, confusion
- Cardiovascular effects: Tachycardia, palpitations
- Gastrointestinal symptoms: Nausea, vomiting, abdominal discomfort
Critical Safety Concerns
The most significant hazard identified is abuse potential 3. This is particularly relevant in ASD populations where:
- Individuals may have difficulty communicating adverse effects
- Caregivers must monitor medication access closely
- The risk-benefit ratio should be carefully considered
Dangerous drug interactions exist with monoamine oxidase inhibitors (MAOIs) 3. Given that autistic individuals frequently take multiple psychotropic medications simultaneously 4, careful medication reconciliation is essential before initiating dextromethorphan.
Special Considerations in ASD
Polypharmacy Context
Autistic adults with intellectual disability take a median of 4 ongoing medications, with 50% under polypharmacy regimens (>4 drugs simultaneously) 4. This creates heightened risk for:
- Drug-drug interactions
- Difficulty attributing adverse effects to specific medications
- Underreporting of adverse events in electronic health records
Detection Challenges
A critical caveat: adverse events are significantly underdetected in ASD populations with intellectual disability 4. Only 64 adverse events were identified over 36 months in 83 adults with ASD and ID, suggesting systematic underreporting rather than true absence of adverse effects.
Age-Specific Dosing
FDA labeling indicates dextromethorphan should not be used in children under 4 years of age 5. For children 4-6 years: 2.5 mL every 12 hours maximum; 6-12 years: 5 mL every 12 hours maximum 5.
Allergic Reactions
Dextromethorphan formulations may contain sodium metabisulfite, which can cause allergic-type reactions 5. This is particularly important in ASD populations where communication of allergic symptoms may be impaired.
Clinical Monitoring Recommendations
When prescribing dextromethorphan to autistic individuals:
- Screen for MAOI use before initiation to avoid potentially dangerous interactions
- Monitor for behavioral changes that may indicate neurological adverse effects, as verbal reporting may be limited
- Assess cardiovascular parameters (heart rate, blood pressure) at baseline and during treatment
- Secure medication storage to prevent accidental overdose or abuse
- Document adverse events systematically, as standard reporting significantly underestimates true incidence in this population 4
The evidence suggests dextromethorphan can be used safely in ASD when appropriate precautions are taken, though clinicians must maintain heightened vigilance for adverse effects that may go unreported due to communication challenges inherent to the disorder.